Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
2022 · Signal Transduction and Targeted Therapy · 236 citations
https://doi.org/10.1038/s41392-022-01042-7
D
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
53
Papers
611
Citations
12
h-index
14
i10-index
Di Gu is an academic researcher from First Affiliated Hospital of Guangzhou Medical University. The author has contributed to research in topics: Prostate Cancer Diagnosis and Treatment & Prostate Cancer Treatment and Research & Renal cell carcinoma treatment. The author has an h-index of 12, co-authored 46 publications.
Papers by this author
worksAssociation between schizophrenia and prostate cancer risk: Results from a pool of cohort studies and Mendelian randomization analysis
2022 · Comprehensive Psychiatry · 15 citations
https://doi.org/10.1016/j.comppsych.2022.152308
A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy
2023 · BMC Medicine · 14 citations
https://doi.org/10.1186/s12916-023-03094-0
Association of body mass index with clinicopathological features among patients with clear cell renal cell carcinoma treated with surgery: a retrospective study
2025 · Scientific Reports · 2 citations
https://doi.org/10.1038/s41598-024-84684-7
Additional file 1 of A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy
2023 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.24439300
USP43 promotes lymphatic metastasis of bladder cancer by regulation of ZBTB7A
2026 · Cellular Signalling · 0 citations
https://doi.org/10.1016/j.cellsig.2026.112433
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat